\n
\n
\n Date
\n Event
\n Sentiment
\n Move
\n Catalyst
\n
\n
\n
\n
\n
\n May 13
\n
\n
\n Earnings webcast notice<\/a>
\n
\n
\n
\n Neutral
\n
\n
\n
\n -2.3%
\n
\n
\n
\n Scheduled webcast to discuss Q1 2026 financial results and business update.
\n
\n
\n
\n
\n Apr 27
\n
\n
\n Clinical presentation<\/a>
\n
\n
\n
\n Positive
\n
\n
\n
\n +1.1%
\n
\n
\n
\n Oral presentation detailing Phase 3 DRAGON topline data for tinlarebant.
\n
\n
\n
\n
\n Apr 23
\n
\n
\n Investor conferences<\/a>
\n
\n
\n
\n Neutral
\n
\n
\n
\n -1.8%
\n
\n
\n
\n Participation in four investor conferences over late April to late May.
\n
\n
\n
\n
\n Apr 21
\n
\n
\n NDA rolling submission<\/a>
\n
\n
\n
\n Positive
\n
\n
\n
\n +3.7%
\n
\n
\n
\n Initiation of rolling NDA submission to FDA for tinlarebant in STGD1.
\n
\n
\n
\n
\n Mar 31
\n
\n
\n Annual report filing<\/a>
\n
\n
\n
\n Neutral
\n
\n
\n
\n +6.9%
\n
\n
\n
\n Announcement of Form 20-F annual report availability for 2025 results.
\n
\n
\n
\n <\/p>\n
Pattern Detected<\/p>\n
Recent clinically focused and regulatory updates have generally seen aligned price reactions, with positive clinical\/regulatory news tending to coincide with modest gains.<\/p>\n
Recent Company History<\/p>\n
Over the past few months, Belite Bio has progressed tinlarebant toward commercialization. On April 21, 2026, it began a rolling NDA submission for Stargardt disease, and on April 27, 2026 highlighted Phase 3 DRAGON topline data showing a 35.7% lesion-growth reduction. Administrative updates, such as the March 31, 2026 Form 20-F notice and conference participation, also drew measurable price moves. Today\u2019s Swiss orphan drug status adds another regulatory milestone to this existing trajectory.<\/p>\n
\n This announcement reinforces tinlarebant\u2019s position after Phase 3 DRAGON success, adding Swiss orphan drug status to existing U.S., European, and Japanese designations. The rolling NDA submission, expected to finish in 2Q 2026, continues the path toward potential commercialization. Historically, Belite\u2019s clinical and regulatory milestones, including the 35.7% lesion-growth reduction data, have coincided with meaningful trading interest. Investors may watch future regulatory updates and any additional trial or safety data for further clarity.
\n <\/p>\n
\n
\n orphan drug status
\n
\n regulatory
\n
\n
<\/p>\n
“Swissmedic has granted tinlarebant… orphan drug status (ODS) for the treatment…”<\/p>\n
An official label from health authorities for medicines that treat very rare diseases, given to encourage development by offering benefits such as reduced fees, tax breaks, and a period of exclusive sales. For investors it matters because these incentives lower development costs and can create a temporary monopoly-like advantage that boosts the drug\u2019s potential revenue and valuation, much like a limited license that makes a risky project more commercially attractive.<\/p>\n
<\/p>\n
\n
\n new drug application (nda)
\n
\n regulatory
\n
\n
<\/p>\n
“initiated a rolling submission of a New Drug Application (NDA) with the U.S. Food…”<\/p>\n
A new drug application (NDA) is a formal request submitted to regulatory authorities to gain approval for a new medication to be sold and used by the public. It is a comprehensive review process that examines the drug\u2019s safety, effectiveness, and manufacturing quality. For investors, an NDA approval can signal a potential breakthrough product and influence a company’s stock value.<\/p>\n
<\/p>\n
\n
\n food and drug administration (fda)
\n
\n regulatory
\n
\n
<\/p>\n
“submission of a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA)…”<\/p>\n
A U.S. government agency that reviews and approves drugs, medical devices, vaccines, food safety measures and related products before they reach the market. Think of it as a gatekeeper whose decisions, inspections and safety warnings can make or break a product\u2019s ability to sell; investors watch FDA actions closely because approvals speed revenue and failed reviews, delays or recalls can sharply change a company\u2019s value.<\/p>\n
<\/p>\n
\n
\n breakthrough therapy
\n
\n regulatory
\n
\n
<\/p>\n
“granted Breakthrough Therapy, Fast Track and Rare Pediatric Disease Designations in the U.S….”<\/p>\n
A breakthrough therapy is a regulatory designation granted to an experimental drug or treatment when early clinical evidence indicates it could offer a substantial improvement over existing options for a serious or life\u2011threatening condition. For investors it matters because the label brings faster, more intensive interaction with regulators and can shorten development and review time\u2014like a VIP fast\u2011track toward potential approval, reducing time and risk before a product can reach the market.<\/p>\n
<\/p>\n
\n
\n fast track
\n
\n regulatory
\n
\n
<\/p>\n
“granted Breakthrough Therapy, Fast Track and Rare Pediatric Disease Designations in the U.S….”<\/p>\n
A fast track designation is a regulatory label that speeds up the review and communication between a drug developer and regulators for treatments addressing serious illnesses or unmet medical needs. For investors, it matters because it can shorten development time and reduce regulatory delays\u2014like getting a VIP lane at the airport\u2014raising the chance of earlier market access and potential revenue, though it does not guarantee approval.<\/p>\n
<\/p>\n
\n
\n rare pediatric disease designation
\n
\n regulatory
\n
\n
<\/p>\n
“Fast Track and Rare Pediatric Disease Designations in the U.S….”<\/p>\n
A rare pediatric disease designation is an official regulatory status given to a drug or therapy that targets a serious or life\u2011threatening condition primarily affecting children and is uncommon in the population. It matters to investors because the status often brings financial and development perks \u2014 such as tax credits, reduced fees, faster review and periods of market protection \u2014 which can lower costs, speed approval and improve the commercial outlook; think of it as a VIP pass that makes bringing a scarce, child\u2011focused treatment to market easier and potentially more profitable.<\/p>\n
<\/p>\n
\n
\n phase 3
\n
\n medical
\n
\n
<\/p>\n
“pivotal, global Phase 3 DRAGON trial Company recently initiated a rolling submission…”<\/p>\n
Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch\u2014like passing a final exam before graduation\u2014and can sharply change a company’s valuation and future revenue prospects.<\/p>\n
<\/p>\n
\n
\n placebo-controlled
\n
\n medical
\n
\n
<\/p>\n
“randomized, double-masked, placebo-controlled, global study designed to evaluate…”<\/p>\n
“Placebo-controlled” describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.<\/p>\n
<\/p>\n
AI-generated analysis. Not financial advice.<\/p>\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n 05\/18\/2026 – 04:00 PM
\n
\n
\n Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease, having met the primary endpoint, reductions in lesion growth rate, in the pivotal, global Phase 3 DRAGON trial\u00a0Company recently initiated a rolling submission of a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA), which it expects to complete in 2Q 2026 Tinlarebant has previously been granted Breakthrough Therapy, Fast Track and Rare Pediatric Disease Designations in the U.S., Orphan Drug Designation in the U.S., Europe, and Japan, and Pioneer Drug Designation in Japan for the treatment of Stargardt disease <\/p>\n
SAN DIEGO, May 18, 2026 (GLOBE NEWSWIRE) — Belite Bio<\/a>, Inc (NASDAQ: BLTE<\/a>) (\u201cBelite Bio\u00ae\u201d or the \u201cCompany\u201d), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted tinlarebant, the Company\u2019s lead product candidate, orphan drug status (ODS) for the treatment of Stargardt disease (STGD1), a rare, inherited retinal disorder caused by mutations in the ABCA4 gene.<\/p>\n \u201cAs the first therapy to demonstrate a clinically meaningful treatment effect in Stargardt disease in a registration trial, tinlarebant provides a potential option for people living with this debilitative disease where there are no currently approved treatments. The importance of bringing this therapy to market is further underscored by the granting of ODS from Swissmedic,\u201d said Dr. Hendrik Scholl, Chief Medical Officer of Belite Bio. \u201cFollowing the successful Phase 3 DRAGON trial, where tinlarebant demonstrated an unprecedented 35.7% reduction in the growth rate of retinal lesions, as measured by retinal imaging, we look forward to bringing this therapy to patients affected by Stargardt disease.\u201d<\/p>\n In December 2025, Belite Bio reported positive results from the Phase 3 DRAGON trial, which was a randomized, double-masked, placebo-controlled, global study designed to evaluate the safety and efficacy of tinlarebant in adolescent patients with Stargardt disease. The trial enrolled 104 subjects across 11 jurisdictions worldwide, including Switzerland, with a 2:1 randomization (tinlarebant:placebo). The primary efficacy endpoint was the growth rate of atrophic lesions, alongside the assessment of safety and tolerability. The trial met its primary efficacy endpoint, demonstrating a statistically significant and clinically meaningful 35.7% reduction in the growth rate of retinal lesions, measured as definitely decreased autofluorescence (DDAF) by fundus autofluorescence imaging, compared with placebo.<\/p>\n About Swissmedics\u2019 Orphan Drug Status About Tinlarebant (a\/k\/a LBS-008) About Belite Bio Important Cautions Regarding Forward Looking Statements Media and Investor Relations Contact:
What did Belite Bio (NASDAQ: BLTE) announce about tinlarebant in Switzerland on May 18, 2026?<\/p>\n
How effective was tinlarebant in the Phase 3 DRAGON trial for Stargardt disease?<\/p>\n
What regulatory designations does tinlarebant have besides Swiss orphan drug status?<\/p>\n
What is the status of Belite Bio\u2019s FDA NDA submission for tinlarebant (BLTE)?<\/p>\n
How many patients were enrolled in Belite Bio\u2019s Phase 3 DRAGON trial of tinlarebant?<\/p>\n
Why is Swissmedic orphan drug status for tinlarebant important for Belite Bio investors?<\/p>\n
Swissmedic grants ODS to encourage the development of treatments for rare, life-threatening, or chronic debilitating diseases that effect less than 5 in 10,000 people in Switzerland through regulatory and financial incentives. Incentives include eligibility for 15 years of document protection (compared to the standard 10 years), qualification for accelerated review timelines, fee reductions, potentially including waiving of the new marketing authorization application flat-rate fee, and potential initiation of an Early Access Pathway, which allows patients to access critical treatments before full marketing authorization is completed.\u00a0<\/p>\n
Tinlarebant is a novel oral therapy that is intended to reduce the accumulation of vitamin A-based toxins (known as bisretinoids) that cause retinal disease in Stargardt disease and also contribute to disease progression in geographic atrophy (GA), or advanced dry age-related macular degeneration (AMD). Bisretinoids are by-products of the visual cycle, which is dependent on the supply of vitamin A (retinol) to the eye. Tinlarebant works by reducing and maintaining levels of serum retinol binding protein 4 (RBP4), the sole carrier protein for retinol transport from the liver to the eye. By modulating the amount of retinol entering the eye, tinlarebant reduces the formation of bisretinoids. Tinlarebant has been granted Breakthrough Therapy Designation, Fast Track Designation, and Rare Pediatric Disease Designation in the U.S., Orphan Drug Designation in the U.S., Europe, Japan, and Switzerland, and Sakigake Designation in Japan for the treatment of Stargardt disease.<\/p>\n
Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as Stargardt disease type 1 and geographic atrophy, in addition to specific metabolic diseases. Belite Bio\u2019s lead candidate, tinlarebant, is an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye. The Company has completed a Phase 3 trial (DRAGON) in adolescent and adult Stargardt disease subjects, and the drug is currently being evaluated in a Phase 2\/3 trial (DRAGON II) in adolescent and adult Stargardt disease subjects and a Phase 3 trial (PHOENIX) in subjects with GA. For more information, follow us on\u00a0X<\/a>,\u00a0Instagram<\/a>,\u00a0LinkedIn<\/a>, and\u00a0Facebook<\/a>, or visit us at\u00a0www.belitebio.com<\/a>.<\/p>\n
This press release contains forward-looking statements regarding future expectations, plans and prospectus, as well as other statements regarding matters that are not historical facts. These statements include but are not limited to statements regarding the potential implications of clinical data for patients, and Belite Bio\u2019s advancement of, and anticipated preclinical activities, clinical development, regulatory milestones, and commercialization of its product candidates, the ability of tinlarebant to treat STGD1 and GA, the timing to complete relevant clinical trials and\/or to receive the interim\/final data of such clinical trials; the timing to submit trial data to regulatory authorities for drug approval, as well as any other statements regarding matters that are not historical facts, and any other statements containing the words \u201cexpect\u201d, \u201cbelieve\u201d, \u201ctarget\u201d, \u201cplan\u201d, \u201chope\u201d, \u201cpotential\u201d and other similar expressions. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors related to Belite Bio\u2019s business, including but not limited to Belite Bio\u2019s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; expectations for the timing of initiation, enrollment and completion of, and data relating to, its clinical trials; the timing to complete any ancillary clinical trials and\/or to receive the interim\/final data of such clinical trials; the timing to communicate with and submit trial data to regulatory authorities for drug approval in various jurisdictions; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Belite Bio\u2019s drug candidates; timing for Belite Bio to share additional data at upcoming medical meetings; the potential efficacy of tinlarebant to set a new benchmark for future research in inherited retinal disorders, as well as those risks more fully discussed in the \u201cRisk Factors\u201d section in Belite Bio\u2019s filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Belite Bio, and Belite Bio undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.<\/p>\n
Jennifer Wu \/ ir@belitebio.com<\/a>
Argot Partners \/ belite@argotpartners.com<\/a><\/p>\n![\"\"](\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/05\/1779136207_949_ti.gif\"\/)
![\"\"](\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/05\/Belite-Bio-Inc.png\")
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
<\/p>\n
\n FAQ
\n <\/p>\n
\n
\n
<\/p>\n
\n Belite Bio announced that Swissmedic granted orphan drug status to tinlarebant for Stargardt disease. According to Belite Bio, this designation supports development of its lead candidate for STGD1, a rare inherited retinal disorder caused by ABCA4 gene mutations, within the Swiss market.
\n <\/p>\n
\n
<\/p>\n
\n Tinlarebant achieved the primary endpoint in the Phase 3 DRAGON trial, reducing retinal lesion growth by 35.7% versus placebo. According to Belite Bio, this randomized, double-masked, placebo-controlled global study in adolescents showed statistically significant and clinically meaningful efficacy on atrophic lesion growth measured by fundus autofluorescence.
\n <\/p>\n
\n
<\/p>\n
\n Tinlarebant has multiple regulatory designations across major regions. According to Belite Bio, it has Breakthrough Therapy, Fast Track and Rare Pediatric Disease designations in the U.S., Orphan Drug status in the U.S., Europe and Japan, and Pioneer Drug designation in Japan for Stargardt disease treatment.
\n <\/p>\n
\n
<\/p>\n
\n Belite Bio has started a rolling New Drug Application submission to the FDA for tinlarebant. According to Belite Bio, the company expects to complete this NDA in the second quarter of 2026, following positive Phase 3 DRAGON trial results in adolescent Stargardt disease patients.
\n <\/p>\n
\n
<\/p>\n
\n The Phase 3 DRAGON trial enrolled 104 adolescent patients with Stargardt disease across 11 jurisdictions worldwide. According to Belite Bio, participants were randomized 2:1 to tinlarebant versus placebo, and the primary endpoint assessed growth rate of atrophic retinal lesions alongside safety and tolerability.
\n <\/p>\n
\n
<\/p>\n
\n Swissmedic orphan drug status supports development of tinlarebant for a rare disease with no approved treatments. According to Belite Bio, this status complements positive Phase 3 data and multiple global designations, potentially strengthening the company\u2019s regulatory position and commercialization prospects if approvals are ultimately obtained.
\n <\/p>\n
\n
\n
\n
\n
\n
\n
<\/p>\n","protected":false},"excerpt":{"rendered":"
Belite Bio (NASDAQ: BLTE) received orphan drug status from Swissmedic for tinlarebant in…\n","protected":false},"author":2,"featured_media":67641,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[4],"tags":[36635,36636,36639,36641,32278,36640,41,36638,17,36637],"class_list":["post-67640","post","type-post","status-publish","format-standard","has-post-thumbnail","category-switzerland","tag-belite-bio","tag-blte","tag-orphan-drug-status","tag-phase-3-dragon","tag-retinal-disease","tag-stargardt-disease","tag-swiss","tag-swissmedic","tag-switzerland","tag-tinlarebant"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116597478427244513","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/67640","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=67640"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/67640\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/67641"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=67640"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=67640"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=67640"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}